57 related articles for article (PubMed ID: 31996596)
1. Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach.
Blashill AJ; Ehlinger PP; Mayer KH; Safren SA
Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S187-90. PubMed ID: 25972502
[TBL] [Abstract][Full Text] [Related]
2. A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation.
Li J; Liu Y; Nehl E; Tucker JD
Curr Opin HIV AIDS; 2024 Jul; 19(4):212-220. PubMed ID: 38686773
[TBL] [Abstract][Full Text] [Related]
3. Appropriate usage of post-exposure prophylaxis-in-pocket for HIV prevention by individuals with low-frequency exposures.
Clifford Rashotte M; Yoong D; Naccarato M; Pico Espinosa OJ; Fisher K; Bogoch II; Tan DH
Int J STD AIDS; 2024 May; 35(6):446-451. PubMed ID: 37963270
[TBL] [Abstract][Full Text] [Related]
4. Patient and Provider Decision Making About HIV Postexposure Prophylaxis Following Sexual Violence: A Qualitative Analysis.
Anderson JC; Boakye MDS; Draughon Moret J
J Assoc Nurses AIDS Care; 2023 Nov-Dec 01; 34(6):566-581. PubMed ID: 37787738
[TBL] [Abstract][Full Text] [Related]
5. Ethical Considerations in Implementing Doxycycline Postexposure Prophylaxis for the Prevention of Bacterial Sexually Transmitted Infections.
Sugarman J; Taylor HA; Bachmann LH; Barbee LA; Cahill S; Celum C; Cohen SE; Faden RR; Luetkemeyer AF; Mayer KH; Mena L; Mermin J; Upshur R; Aral S
Sex Transm Dis; 2024 Mar; 51(3):135-138. PubMed ID: 38079243
[No Abstract] [Full Text] [Related]
6. Planning for PrEP: are national surveillance data sufficient?
Rutstein SE; Miller WC
Lancet HIV; 2023 Dec; 10(12):e759-e760. PubMed ID: 38040473
[No Abstract] [Full Text] [Related]
7. Changing costs of preexposure prophylaxis may undermine efforts to curb HIV infection rates.
Filip I
AIDS; 2024 Jun; 38(7):N11-N12. PubMed ID: 38489576
[No Abstract] [Full Text] [Related]
8. Women-Centered Program for Women of Color (WC4WC): A Community-Based Participatory, Culturally Congruent Sexual Health Intervention in Los Angeles County, California.
Wyatt GE; Chin D; Loeb TB; Norwood-Scott E; McEwan JA; Zhang M; Smith-Clapham AM; Cooley-Strickland M; Trinidad C; Flint JR; Wells Y; Divinity R; Liu H
Am J Public Health; 2023 Jun; 113(S2):S110-S114. PubMed ID: 37339413
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive specialty pharmacist support for HIV postexposure prophylaxis in a health system-based emergency department setting.
Jude D
Am J Health Syst Pharm; 2024 Apr; 81(8):265-269. PubMed ID: 38141253
[No Abstract] [Full Text] [Related]
10. Validation of HIV Pre-Exposure Prophylaxis (PrEP) Medication Scales with Youth on PrEP: PrEP Confidence Scale and PrEP Difficulties Scale.
Budhwani H; Yigit I; Maragh-Bass AC; Rainer CB; Claude K; Muessig KE; Hightow-Weidman LB
AIDS Patient Care STDS; 2022 Nov; 36(11):443-450. PubMed ID: 36306520
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of the Youth Pre-Exposure Prophylaxis (PrEP) Stigma Scale.
Budhwani H; Yiğit İ; Maragh-Bass AC; Rainer CB; Claude K; Muessig KE; Hightow-Weidman LB
AIDS Behav; 2023 Mar; 27(3):929-938. PubMed ID: 36029425
[TBL] [Abstract][Full Text] [Related]
12. Self-Reported Sexual Behavioral Similarities and Differences Among Young Men Who Have Sex With Men With Childhood Sexual Abuse Histories: A Qualitative Exploratory Study.
Emetu RE; Yarber WL; Sherwood-Laughlin CM; Brandt AS
Am J Mens Health; 2020; 14(4):1557988320949355. PubMed ID: 32772691
[TBL] [Abstract][Full Text] [Related]
13. The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.
Jain S; Krakower DS; Mayer KH
Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S200-4. PubMed ID: 25972505
[TBL] [Abstract][Full Text] [Related]
14. HIV postexposure prophylaxis-in-pocket: long-term follow-up of individuals with low-frequency, high-risk HIV exposures.
Alghamdi A; Hempel A; Heendeniya A; Clifford-Rashotte M; Tan DHS; Bogoch II
AIDS; 2020 Mar; 34(3):433-437. PubMed ID: 31996594
[TBL] [Abstract][Full Text] [Related]
15. Brief Report: HIV Postexposure Prophylaxis-in-Pocket ("PIP") for Individuals With Low-Frequency, High-Risk HIV Exposures.
Tumarkin E; Heendeniya A; Murphy P; Placido T; Tan DHS; Bogoch II
J Acquir Immune Defic Syndr; 2018 May; 78(1):20-22. PubMed ID: 29419570
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral Medications for the Prevention of HIV Infection: A Clinical Approach to Preexposure Prophylaxis, Postexposure Prophylaxis, and Treatment as Prevention.
Heendeniya A; Bogoch II
Infect Dis Clin North Am; 2019 Sep; 33(3):629-646. PubMed ID: 31239092
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoprevention of Human Immunodeficiency Virus Infection.
Yingling C; Broholm C; Stephenson S
Nurs Clin North Am; 2020 Sep; 55(3):429-444. PubMed ID: 32762861
[TBL] [Abstract][Full Text] [Related]
18. Prevention of HIV for persons with low-frequency, high-risk exposures: PrEP (preexposure prophylaxis), PEP (postexposure prophylaxis), or 'PIP' (postexposure prophylaxis in-pocket).
Wood BR
AIDS; 2020 Mar; 34(3):481-482. PubMed ID: 31996596
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
